SIRT1 and Hyperglycemia: Astragaloside-IV can enhance SIRT1 and Nrf2 activity, boost cellular antioxidant capacity, reduce hyperglycemia-induced ferroptosis, and protect retinal pigment epithelial (RPE) cells from damage, offering a potential therapeutic strategy for DR (Tang et al., 2022).